이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

자궁내막암의 감시림프절 생검 (ENDO-3)

2026년 11월 11일 업데이트: Queensland Centre for Gynaecological Cancer

겉보기 초기 자궁내막암에서 후복막 결절 절제술을 시행하지 않는 감시림프절 생검과 비교하는 3상 무작위배정 임상시험

Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC typically includes removal of the uterus and to determine the extent of the disease (removal of fallopian tubes, ovaries & if required a lymph node dissection (surgical staging)). While lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In some patients it causes morbidity, specifically lymphoedema. This recently has been replaced with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with specific equipment & surgical dissection of the lymph node in which the dye first becomes visible. Despite this promising proposition & similar to a lymph node dissection, the value to patients, cost effectiveness & potential harms (e.g. lymphedema) of SNB compared to no-node dissection in EC has never been established. Aim: determine the value of SNB for patients, the healthcare system and exclude detriment to patients using a randomised approach 1:1. Stage 1 - 444 patients. Stage 2 additional 316 patients.

Primary Outcome Stage 1:

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

Primary Outcome Stage 2:

Treatment non-inferiority as evaluated by disease-free survival status at 4.5 years post-surgery, as measured by the time interval between the date of randomisation and date of first recurrence. Confirmation of recurrent disease will be ascertained through clinical assessment, radiological work-up and/or histological results.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Hypothesis: The primary hypothesis is that SNB will not cause detriment to patients (lymphoedema, morbidity, loss of quality of life) and not increase costs compared to patients without a retroperitoneal node dissection. The secondary hypothesis is that disease-free survival in patients without retroperitoneal node dissection is not inferior to those receiving SNB.

Aims: To determine the value of SNB for patients, the healthcare system and to exclude detriment to patients.

Objectives:

Primary Stage 1:

To determine the recovery of participants (defined as incidence of adverse events, lower limb lymphoedema and health-related QOL) and to the healthcare system (cost) of Sentinel Node Biopsy (SNB) for the surgical treatment of endometrial cancer.

Primary Stage 2:

Compare disease-free survival at 4.5 years for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.

Secondary:

  • Compare patterns of recurrence and overall survival (OS) between the groups
  • Determine the cost-effectiveness of SNB
  • Compare Patient Reported Outcomes (PROMS) between the groups at 12 months from surgery
  • Compare Health Related Quality of Life (HRQL) and Fear of Recurrence between the groups at 12 months from surgery
  • Compare perioperative outcomes (duration of surgery, length of hospital stay, intraoperative blood loss, blood transfusion requirements) and the incidence of intra- and postoperative adverse events within 12 months from surgery between the groups
  • Compare lower limb lymphoedema at 12 months after surgery
  • Compare the need for postoperative (adjuvant) treatments between groups
  • Determine the impact of body composition and frailty on survival, quality of life, lymphoedema, peri-, intra- and postoperative outcomes
  • Compare follow-up strategies (clinical vs symptom checklist)
  • Translational Research - Trans-ENDO 3 - biobanking strategy - Compare the Molecular profile at 12 months from surgery between the groups

연구 유형

중재적

등록 (추정된)

760

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Texas
      • Houston, Texas, 미국, 77030
        • 모병
        • Houston Methodist Hospital
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Behrouz Zand, MD
        • 부수사관:
          • Tarrik Zaid, MD
        • 부수사관:
          • Aparna Kamat, MD
        • 부수사관:
          • Anju Suri, MD
        • 부수사관:
          • Pedro Ramirez, MD
    • São Paulo
      • São José do Rio Preto, São Paulo, 브라질, 15090-000
      • São Paulo, São Paulo, 브라질
      • São Paulo, São Paulo, 브라질
        • 모병
        • Hospital Israelita Albert Einstein
        • 연락하다:
        • 연락하다:
          • Renato
        • 수석 연구원:
          • Renato Moretti-Marques, MD
    • NUH Zone B
      • Singapore, NUH Zone B, 싱가포르, 119074
        • 모병
        • National University Hospital and National University Cancer Institute
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • Joseph Ng Soon Yau, MD
        • 부수사관:
          • Pearl S Tong, MD
        • 부수사관:
          • Jeffrey Low, MD
        • 부수사관:
          • Jeslyn Wong, MD
    • Ciudad Autónoma de Buenos Aires (caba)
      • Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), 아르헨티나
      • Buenos Aires, Ciudad Autónoma de Buenos Aires (caba), 아르헨티나
        • 모병
        • Hospital Britanico
        • 연락하다:
        • 수석 연구원:
          • Julian Di Guilmi, MD
    • Antioquia
      • Medellín, Antioquia, 콜롬비아, 050025
        • 모병
        • Promotora Médica Las Américas S.A.
        • 연락하다:
        • 수석 연구원:
          • Gabriel Rendon, MD
    • Bogotá, Distrito Capital
      • Bogotá, Bogotá, Distrito Capital, 콜롬비아, 110131
        • 모병
        • Centro de tratamiento e investigación sobre Cáncer Luis Carlos Sarmiento Angulo
        • 연락하다:
        • 연락하다:
        • 수석 연구원:
          • David Viveros, MD
    • New South Wales
      • Camperdown, New South Wales, 호주, 2050
      • Liverpool, New South Wales, 호주, 2170
    • Queensland
      • Auchenflower, Queensland, 호주, 4066
        • 모병
        • The Wesley Hospital
        • 연락하다:
        • 수석 연구원:
          • Andrea Garrett, MD
        • 부수사관:
          • Rhett Morton, MD
        • 연락하다:
      • Brisbane, Queensland, 호주, 4120
      • Buderim, Queensland, 호주, 4556
      • Everton Park, Queensland, 호주, 4053
      • Herston, Queensland, 호주, 4029
        • 모병
        • Royal Brisbane and Women's Hospital
        • 연락하다:
        • 수석 연구원:
          • Andrea Garrett, MD
        • 부수사관:
          • Andreas Obermair, MD
        • 부수사관:
          • Russell Land, MD
        • 부수사관:
          • Piksi Singh, MD
        • 부수사관:
          • Shaun McGrath, MD
        • 연락하다:
      • South Brisbane, Queensland, 호주, 4101
        • 모병
        • Mater Hospital
        • 연락하다:
        • 부수사관:
          • Nisha Jagasia, MD
        • 부수사관:
          • Nimithri Cabraal, MD
        • 부수사관:
          • Rhett Morton, MD
        • 수석 연구원:
          • Naven Chetty, MD
        • 연락하다:
        • 부수사관:
          • Simon West, MD
      • Southport, Queensland, 호주, 4215
        • 아직 모집하지 않음
        • Gold Coast University Hospital
        • 연락하다:
        • 수석 연구원:
          • Elizabeth Goulding, MD
        • 연락하다:
      • Spring Hill, Queensland, 호주, 4000
        • 모병
        • St Andrews War Memorial Hospital
        • 연락하다:
        • 수석 연구원:
          • Andreas Obermair, MD
        • 연락하다:
    • Victoria
      • Heidelberg, Victoria, 호주, 3084
      • Melbourne, Victoria, 호주, 3002
        • 모병
        • Epworth Freemasons
        • 연락하다:
        • 수석 연구원:
          • Adam Pendlebury, MD
      • Parkville, Victoria, 호주, 3052

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

여성

설명

Inclusion Criteria:

  1. Females, over 18 years, with histologically confirmed primary epithelial cancer of the endometrium of any cell type or uterine carcinosarcoma (mixed malignant mullerian tumour);
  2. Clinically stage I disease (disease confined to body of uterus);
  3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2;
  4. Signed written informed consent;
  5. Participant must meet criteria for a laparoscopic or robotic surgical approach as determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate Trendelenberg positioning)
  6. All available clinical evidence (physical examination findings, or medical imaging such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease
  7. Myometrial Invasion on MRI of not more than 50%. (Only if participant is <45yo, has ONLY Grade 1 EAC and wishes to retain their ovaries).
  8. Negative (serum or urine) pregnancy test ≤ 30 days of surgery in pre-menopausal women and women < 2 years after the onset of menopause.

Exclusion Criteria:

  1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria, adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or through medical imaging.
  2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (>1 cm) on medical imaging;
  3. Estimated life expectancy of less than 6 months;
  4. Patients who have absolute contraindications for adjuvant radiotherapy and/or chemotherapy;
  5. Patients who have previously received radiation treatment to the pelvis
  6. Serious concomitant systemic disorders incompatible with the study (at the discretion of the investigator);
  7. Patient compliance and geographic proximity that do not allow adequate follow-up;
  8. Patients with allergy to Indocyanine Green (ICG)
  9. Patients who have had previous retroperitoneal surgery
  10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection (lymphadenectomy)
  11. Other prior malignancies <5 years before inclusion, except for successfully treated keratinocyte skin cancers, or ductal carcinoma of the breast insitu
  12. Uterine perforation during endometrial tissue sampling

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: TH BSO with SNB

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG)+/- Methylene Blue Dye (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) +/- Methylene Blue Dye is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the "sentinel node". These one or two nodes are thought to be first involved with cancer spread.

활성 비교기: TH BSO without retroperitoneal node dissection

Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types) Note: If participants (≤45 years of age), have Grade 1 endometrial adenocarcinoma (EAC) with myometrial invasion <50% (by MRI) and wish to retain their ovaries a BSO may be omitted.

Removal of uterus, tubes and ovaries without retroperitoneal node dissection

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Stage 1: Return to usual activities
기간: 12 months from surgery

Proportion of participants returning to usual daily activities at 12 months from surgery using the EQ-5D which will determine when women in both groups can return to their usual activities.

12 months from surgery
Stage 2: Disease Free Survival
기간: 4.5 years from surgery

Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery

2차 결과 측정

결과 측정
측정값 설명
기간
Cost Effectiveness using QALYs using EuroQoL-5D (EQ-5D) Questionnaire
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D

12 months from surgery
Cost Effectiveness measuring Intervention costs
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring GP and specialist consultations
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring radiology and imaging requirements
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Cost Effectiveness measuring prescriptions and over the counter medicine requirements
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness measuring community and health service requirements and days off work and informal care required by family and friends using a combination of the Health Services Questionnaire and clinical files
기간: 12 months from surgery

An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life.

12 months from surgery
Cost Effectiveness: direct costs using a bottom-up approach by recording the volume of resource use in both groups of the trial, and then applying a unit cost to each component
기간: 12 months from surgery

Direct costs wukk be ibtained for smaples of participants, stratified by hospital, operation and outcome to assess the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society.

12 months from surgery
Perioperative Outcomes: Adverse Events
기간: 12 months from surgery

Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5)

12 months from surgery
Perioperative Outcomes: Length of Surgery
기간: At time of surgery

Compare the length of surgery between the two groups. This will be recorded in hh:mm on the surgery form.

At time of surgery
Perioperative Outcomes: Blood Loss during Surgery
기간: At time of surgery

Compare the blood loss between the two groups during surgery. This will be recorded in ml.

At time of surgery
Perioperative Outcomes: Blood Transfusion Requirements during Surgery
기간: At time of surgery

Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form.

At time of surgery
Perioperative Outcomes: Length of Hospital Stay
기간: At time of discharge from hospital following surgery

Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0.

At time of discharge from hospital following surgery
Health Related Quality of Life and Fear of Recurrence
기간: 12 months from surgery

Change in Quality of Life using Functional Assessment of Cancer General (FACT-EN), Fear of Recurrence and PROMS between baseline and 1 year after surgery

12 months from surgery
Incidence of Lymphedema
기간: 12 months from surgery

Compare lower limb lymphedema between groups

12 months from surgery
Adjuvant Treatment Requirements
기간: 12 months from surgery

Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates.

12 months from surgery
Value of Molecular Biomarkers
기간: 24 months from surgery

Translational Research - Compare Molecular profile from surgery between the groups that require adjuvant therapy for 24 months.

24 months from surgery
Value of Molecular Biomarkers
기간: 12 months from surgery

Translational Research - Compare the Molecular profile of Germline DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
기간: 12 months from surgery

Translational Research - Compare the Molecular profile of Circulating Tumour DNA at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
기간: 12 months from surgery

Translational Research - Compare the Molecular profile of Plasma at 12 months from surgery between the groups

12 months from surgery
Value of Molecular Biomarkers
기간: 12 months from surgery

Translational Research - Compare the Molecular profile of Serum at 12 months from surgery between the groups

12 months from surgery
Overall Survival
기간: 4.5 years from surgery

Compare overall survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection

4.5 years from surgery
Patterns of Recurrence - date and localization of 1st recurrence
기간: 4.5 years from surgery

Date and localization of 1st recurrence as confirmed histologically and/or radiologically - Compare these patterns of recurrences between the groups. These will also be adjudicated by an independent committee to ensure accuracy of documented recurrence

4.5 years from surgery
Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival
기간: 4.5 years from surgery

Body mass measures are practical & sensitive for predicting health risks & outcomes. Sarcopenia is defined as loss of skeletal muscle mass & strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images & Bioimpedance Spectroscopy (BIS - if available at site) & postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events & participants tolerability of treatment & compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement & analysis of impedance to currents by extracellular fluid

4.5 years from surgery
Impact of frailty on surgical complications, recovery and overall survival
기간: 4.5 years from surgery

It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes

4.5 years from surgery
Follow-Up Strategies
기간: 4.5 years from surgery

Current institutional & clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery & the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years & 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients.

4.5 years from surgery

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 의자: Andreas Obermair, Prof, Director, Queensland Centre for Gynaecological Cancer Research

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 1월 18일

기본 완료 (추정된)

2031년 1월 1일

연구 완료 (추정된)

2031년 2월 1일

연구 등록 날짜

최초 제출

2019년 8월 26일

QC 기준을 충족하는 최초 제출

2019년 8월 27일

처음 게시됨 (실제)

2019년 8월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 16일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • ENDO-3

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .